Cleveland HeartLab LLC Adds New Patent To Its Extensive Intellectual Property Position For The Myeloperoxidase (MPO) Test, A Powerful Biomarker For Inflammation And Its Role In Major Cardiac Events

Published: Feb 22, 2017

CLEVELAND, Feb. 22, 2017 /PRNewswire/ -- Cleveland HeartLab Inc. (CHL), the premier cardiovascular disease (CVD) management company, announced today that a new patent for Myeloperoxidase (MPO) testing has been issued, U.S. Patent No. 9,575,065.  Cleveland HeartLab is the exclusive license holder for MPO testing, which is covered by a number of patents including this newly issued patent.  Originally discovered and developed at the Cleveland Clinic, MPO testing has been recognized in over 100 peer-reviewed publications as a key measure of vascular inflammation.  This new patent will add to Cleveland HeartLab's already existing portfolio of intellectual property rights, which include 24 issued patents and an additional 17 pending patent applications.

"This latest patent increases our intellectual property portfolio and further demonstrates Cleveland HeartLab's leadership in bringing valuable and innovative tests to market," said Jake Orville, President and CEO of Cleveland HeartLab.

According to the U.S. Department of Health and Human Services, Americans suffer 1.5 million heart attacks and strokes each year. CVDincluding heart disease and strokeis the leading cause of death in the U.S. Every day, 2,200 people die from CVDthat's nearly 800,000 Americans each year, or 1 in every 3 deaths.  According to the American Heart Association, half of those who suffer heart attacks and strokes have "normal" cholesterol levels, so tools such as MPO testing are desperately needed to improve our ability to assess CVD risk in patients whose risk is not revealed by cholesterol testing alone.  The U.S. spends approximately $4 trillion on healthcare annually, one-sixth of which is spent treating CVD, according to the Centers for Disease Control and Prevention.

A recent publication in the Journal of Medical Economics demonstrated the use of MPO testing in combination with standard lipid testing could reduce heart attacks and strokes by approximately 10% compared to traditional cholesterol testing alone, not only saving lives but also hundreds of millions of healthcare dollars.

About Cleveland HeartLab 

Cleveland HeartLab Inc. is the premier cardiovascular disease (CVD) Management Company with a comprehensive array of propriety tests focused on improving the early identification of those with CVD risk. In addition to its industry leading approach to inflammation testing, CHL manages a robust R&D program to accelerate the clinical use of scientifically proven and medically relevant biomarkers. CHL's biomarkers have been validated in more than 100 peer-review studies published in leading medical and scientific journals. Formed in 2009 as a spin-off from the Cleveland Clinic, CHL offers its testing to thousands of leading clinicians focused on health and wellness as well as corporate wellness plans through its CAP-accredited and CLIA-certified clinical lab. Half of all patients who suffer from heart attack have normal cholesterol. With the goal of improving CVD risk assessment, CHL's unique testing provides a more complete picture of CVD risk allowing clinicians to deploy personalized medical programs and interventions to reduce the overall risk of CVD, with a specific focus on reducing the risks of inflammation. CHL has been recognized for its innovation with the prestigious Nortech Innovation Award, The Ohio Venture of the Year Award and the Edison Crystal Award for Excellence. CHL was also named an "Inc. 5,000" company in recognition of its innovation and growth. For more information about CHL visit us at www.clevelandheartlab.com. For more information on CVD visit www.knowyourrisk.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cleveland-heartlab-adds-new-patent-to-its-extensive-intellectual-property-position-for-the-myeloperoxidase-mpo-test-a-powerful-biomarker-for-inflammation-and-its-role-in-major-cardiac-events-300410736.html

SOURCE Cleveland HeartLab Inc.

Back to news